Ondansetron

Shook Taps Partner to Lead New Litigation Strategy Practice Focusing on Co-Counsel Collaboration

Retrieved on: 
Thursday, February 8, 2024
Shook, Hardy & Bacon, MDL, Virtual law firm, Partnership, Ranitidine, Docetaxel, Judicial panel, Product liability, Essure, Lawyer, Ondansetron, CLSC, VLF, Motion

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- Trial and litigation firm Shook, Hardy & Bacon has named Partner Jennifer Stevenson as co-chair of its newly formed Complex Litigation Strategic Counseling (CLSC) Practice, alongside Partner Patrick Oot. This cross disciplinary group includes the firm's Chambers-ranked Discovery Strategies Practice, which will continue to provide creative and defensible discovery solutions, while offering an array of new strategic counseling services to clients navigating the coordination challenges of mass torts and multidistrict litigation.

Key Points: 
  • WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- Trial and litigation firm Shook, Hardy & Bacon has named Partner Jennifer Stevenson as co-chair of its newly formed Complex Litigation Strategic Counseling (CLSC) Practice, alongside Partner Patrick Oot .
  • "Our Complex Litigation Strategic Counseling Practice offers clients a holistic approach to effectively and efficiently manage multidistrict litigation," said Stevenson.
  • Her litigation successes include pioneering the motion to dismiss and show cause strategy in the In re Zofran (Ondansetron) Products Liability Litigation MDL.
  • "Shook's long history as strategic coordinating counsel in MDLs, mass torts and complex litigation is second to none," said Shook Chair Madeleine McDonough .

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Retrieved on: 
Wednesday, October 18, 2023
Patient, Abdominal pain, DGP, Standard of care, American College, Stomach, ACG, University of California, Diabetes, American College of Gastroenterology, Texas Tech University Health Sciences Center El Paso, Gastroparesis, Nausea, GERD, Metoclopramide, Evoke, University, Ondansetron, ER, Cleveland Clinic, DDW, Pharmaceutical industry, MD

These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).

Key Points: 
  • These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).
  • Upon identifying a major gap in gastroparesis treatment, Evoke developed GIMOTI as a nasal spray to specifically by-pass erratic absorption issues that DGP patients often suffer with medications that are in tablet or pill form.
  • Patients with long-standing diabetes can develop gastroparesis (a delay in stomach emptying).
  • “With the lack of effective oral treatments, and the promising findings for GIMOTI, Evoke is dedicated to make GIMOTI the standard of care for patients with diabetic gastroparesis,” said Dave Gonyer, R.Ph., Evoke Pharma CEO.

RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

Retrieved on: 
Monday, May 1, 2023
Patent, Marketing, Cancer, Vomiting, MHRA, TEL, Radiation, Patient, European Patent Convention, European Patent Office, Nausea, Ondansetron, Pharmaceutical industry, EU

TEL AVIV, Israel and RALEIGH, N.C., May 1, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the granting of two new EU and U.S. patents for RHB-102 (BEKINDA)1 and opaganib2, respectively, in the oncology setting.

Key Points: 
  • The European Patent Office granted RHB-102 (BEKINDA), a 24-hr bimodal release, once-daily oral tablet formulation of ondansetron, a patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV).
  • The patent provides the potential for UK and EU protection of RHB-102 to March 2034.
  • "Between 70-80% of patients undergoing chemotherapy or radiotherapy will experience nausea and/or vomiting.
  • Additionally, the U.S. Patent and Trademark Office (USPTO) has granted a new patent for opaganib in respect to combination compositions for treatment of cancer, extending protection to October 2036.

Boasso Global and Quala to Merge, Creating a Leading Infrastructure Service Provider for Liquid Bulk Logistics Industry

Retrieved on: 
Thursday, February 9, 2023
Asset Management, Professional Services, Finance, Organization, ISO, LLP, Investment, Simpson Thacher & Bartlett, Safety, Maintenance, Weil, Gotshal & Manges, Ecosystem, Citigroup, Culture, Credit Suisse, KKR, Advent International, Bank of America, Growth, Bank, IBC, Ondansetron, Management

Boasso Global, Inc. (“Boasso”) and Q Super Holdings, Inc. (“Quala”) today announced the signing of a definitive agreement under which the companies will merge their complementary businesses to create one of the leading infrastructure services solution providers for the liquid bulk logistics industry.

Key Points: 
  • Boasso Global, Inc. (“Boasso”) and Q Super Holdings, Inc. (“Quala”) today announced the signing of a definitive agreement under which the companies will merge their complementary businesses to create one of the leading infrastructure services solution providers for the liquid bulk logistics industry.
  • The transaction is supported by a new investment from Boasso’s majority shareholder, KKR, through its KKR Global Infrastructure Investors IV fund.
  • Upon completion of the merger, the companies will combine their complementary geographical footprints and service offerings to deliver enhanced solutions for customers across the liquid bulk logistics industry in North America and Europe.
  • “Boasso and Quala are premier infrastructure service providers to the global liquid bulk logistics ecosystem with trusted reputations and highly complementary networks and service offerings,” said Dash Lane, Partner at KKR.

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

Retrieved on: 
Friday, February 3, 2023
Vomiting, Palonosetron, Future Oncology, CINV, Nausea, Hospital, APON, Patient, Use, APPA, Precision medicine, NEPA, Degenerative disease, Research, Ondansetron, Medical imaging

The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.

Key Points: 
  • The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.
  • NEPA was compared to aprepitant/fosaprepitant-containing regimens among patients who received highly or moderately emetogenic chemotherapy in the US.
  • The study findings suggest that the downstream economic impact of antiemetic choice may differ depending on the combination of treatments.
  • Hospitalizations with CINV as the primary reason for admission were identified and all incurred costs for these hospital stays were used in the cost accounting.

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)

Retrieved on: 
Friday, September 16, 2022
Headache, Dizziness, Condom, Bachelor of Medicine, Bachelor of Surgery, Cochrane, Milk, FRCA, IV, Master of Science, COVID-19, Pain, Heron, Risk, Brain, FDA, Food, Ondansetron, Hormone, Vomiting, U.S. Securities and Exchange Commission, Division, Company, Intrauterine device, News, Private Securities Litigation Reform Act, Achievement, Pharming, Therapy, Forward-looking statement, Patient satisfaction, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Pregnancy, Physician, Duke University Hospital, Standard of care, Antiemetic, Investor relations, Media, Media contacts database, NASDAQ, PONV, Allergy, Clinician Administered PTSD Scale, SAN, Vitamin, Constipation, Aprepitant, Warfarin, Webcast, CINV, Drug discovery, MHSC, Plasma, Fatigue, Pharmaceutical industry, Birth control, Woman, Anesthesia

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Key Points: 
  • Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to ondansetron.
  • "With the approval of APONVIE our acute care portfolio now addresses the two most common concerns of patients and clinicians after surgery, postoperative pain and postoperative nausea and vomiting.
  • APONVIE (aprepitant) injectable emulsion is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • APONVIE is the same formulation as Heron's approved CINVANTI (aprepitant) injectable emulsion formulation for prevention of chemotherapy-induced nausea and vomiting (CINV).

Worldwide Hydroxytryptamine Receptor Blocker Industry to 2027 - by Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 5, 2022
Health, Pharmaceutical, Vomiting, Cayman Chemical Company, Cyproheptadine, Ondansetron, Government, CAGR, Tropisetron, Granisetron, Nausea, Pharmaceutical industry, Marketing

The global hydroxytryptamine receptor blocker market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global hydroxytryptamine receptor blocker market is anticipated to grow at a considerable CAGR during the forecast period.
  • The global hydroxytryptamine receptor blocker market is segmented based on type and application.
  • Based on application, the hydroxytryptamine receptor blocker market is segmented into medical care, scientific research, and other.
  • Some of the companies operating in the global hydroxytryptamine receptor blocker market include Wako Pure Chemical Industries, Otava Chemicals, Cayman Chemical.

Pharmascience Canada Launches pms-ONDANSETRON ODT, a Generic Medicine with Multiple Indications!

Retrieved on: 
Monday, April 18, 2022
People, Tablet, Life, R, Cisplatin, Novartis, Research and development, Maintenance, Investment, Safety, Radiation, Vomiting, Ondansetron, Canada's Top 100 Employers, Nausea, Pharmaceutical industry, Platinum

MONTREAL, April 18, 2022 /CNW Telbec/ - Pharmascience Canada is proud to launch PRpms-ONDANSETRON ODT tablets in 4 mg and 8 mg!

Key Points: 
  • MONTREAL, April 18, 2022 /CNW Telbec/ - Pharmascience Canada is proud to launch PRpms-ONDANSETRON ODT tablets in 4 mg and 8 mg!
  • With the same safety and efficacy profile to the brand name product, PRpms-ONDANSETRON ODT is available at a lower cost.
  • Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal.
  • Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries.

Sunovion Presents New KYNMOBI® (apomorphine sublingual film) Study Data at the International Parkinson and Movement Disorder Society (MDS) Congress 2021

Retrieved on: 
Friday, September 10, 2021
Biotechnology, Pharmaceutical, Health, Other Health

Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinsons disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinsons disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.
  • The presentations include post-hoc findings from the pivotal study (CTH-300) and findings from an ongoing long-term safety study (CTH-301) of KYNMOBI.
  • These episodes rarely impacted patients ability to continue treatment with KYNMOBI.
  • Do not use KYNMOBI if you are allergic to apomorphine hydrochloride or to any of the ingredients in KYNMOBI.